Global Heart Valve Repair And Replacement Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Heart Valve Repair and Replacement Market Size

• The global heart valve repair and replacement market size was valued at USD 5.53 billion in 2024 and is expected to reach USD 13.02 billion by 2032, at a CAGR of 11.30% during the forecast period
• The market growth is largely fueled by the rising prevalence of valvular heart diseases, aging global population, and advancements in minimally invasive surgical techniques and transcatheter therapies
• Furthermore, increasing awareness, supportive reimbursement frameworks, and growing healthcare expenditure are establishing heart valve interventions as critical components in modern cardiovascular care. These converging factors are accelerating the adoption of repair and replacement procedures, thereby significantly boosting the industry's growth

Heart Valve Repair and Replacement Market Analysis

• Heart valve repair and replacement, encompassing surgical and transcatheter interventions, are increasingly vital components of modern cardiovascular care in both hospital and ambulatory settings due to their life-saving role, technological advancements, and growing clinical acceptance of minimally invasive procedures
• The escalating demand for heart valve therapies is primarily fueled by the rising prevalence of valvular heart diseases, aging populations, and increasing awareness about early diagnosis and timely intervention
• North America dominated the heart valve repair and replacement market with the largest revenue share of 39.2% in 2024, characterized by advanced healthcare infrastructure, high procedure volumes, favorable reimbursement policies, and the presence of key industry players, with the U.S. experiencing significant procedural growth driven by innovations in transcatheter aortic valve replacement (TAVR) and mitral repair technologies
• Asia-Pacific is expected to be the fastest growing region in the heart valve repair and replacement market during the forecast period due to increasing healthcare access, medical tourism, and improving diagnostic capabilities
• TAVI/TAVR Valves segment dominated the heart valve repair and replacement market with a market share of 44.1% in 2024, driven by its minimally invasive nature, shorter recovery times, and increasing adoption among high-risk and elderly patients unsuitable for open-heart surgery

Report Scope and Heart Valve Repair and Replacement Market Segmentation       

Heart Valve Repair and Replacement Market Trends

“Technological Innovation Driving Minimally Invasive Procedures”

• A significant and accelerating trend in the global heart valve repair and replacement market is the advancement of minimally invasive and transcatheter-based procedures, such as Transcatheter Aortic Valve Replacement (TAVR), which are transforming the treatment landscape for valvular heart diseases by reducing surgical risk and improving recovery times
  • For instance, Edwards Lifesciences and Medtronic have introduced next-generation TAVR systems with enhanced delivery precision, improved valve positioning, and reduced paravalvular leakage. These innovations are enabling broader application of the technique in intermediate- and even low-risk patient populations
• Miniaturized catheter technologies and improved valve materials are contributing to fewer complications, shorter hospital stays, and faster patient recovery, which is accelerating acceptance among cardiologists and patients asuch as. For instance, Abbott’s MitraClip system offers a less invasive alternative for mitral valve repair in patients at prohibitive surgical risk
• These trends are being supported by increasing clinical evidence and guideline endorsements, which are helping to shift standard care practices towards catheter-based therapies. Furthermore, enhanced imaging modalities such as 3D echocardiography and cardiac CT are enabling more precise patient selection and procedural planning
• The integration of real-time imaging, robotic assistance, and AI-driven diagnostics is further streamlining the procedure, reducing variability, and improving long-term patient outcomes. As a result, leading manufacturers are investing in research collaborations and clinical trials to expand indications for transcatheter valve systems
• The trend toward innovation in heart valve repair and replacement is reshaping expectations for less invasive, safer, and more accessible cardiac interventions, paving the way for increased procedural volumes and improved quality of life for patients globally

Heart Valve Repair and Replacement Market Dynamics

Driver

“Rising Burden of Valvular Heart Disease and Aging Population”

• The increasing global incidence of valvular heart diseases (VHDs), especially aortic stenosis and mitral regurgitation, coupled with the aging population, is a major driver for the growing demand for heart valve repair and replacement therapies
  • For instance, according to the American Heart Association, over 13% of people aged above 75 are affected by moderate to severe VHD, creating a large and growing patient population in need of intervention
• This demographic shift is intensifying the need for both surgical and transcatheter solutions that offer improved survival rates and reduced procedural risk. Healthcare systems and clinicians are increasingly turning to minimally invasive approaches to reduce hospitalization time and increase patient throughput
• In addition, favorable reimbursement policies in developed markets, rising awareness campaigns, and improved diagnostic capabilities are further supporting early intervention and timely treatment of VHDs
• Continuous innovation in valve design, improved device durability, and expansion of transcatheter options beyond the aortic valve are also boosting clinical confidence and market expansion

Restraint/Challenge

“High Cost and Limited Access in Low-Resource Settings”

• The high cost of advanced valve replacement devices and associated procedures, especially transcatheter therapies, remains a significant barrier to widespread adoption in many low- and middle-income countries
  • For instance, TAVR procedures can cost up to USD 40,000 in some markets, placing them out of reach for many patients lacking comprehensive insurance coverage or public health funding
• In addition to financial barriers, access to specialized healthcare infrastructure and skilled interventional cardiologists is limited in many regions, restricting availability of advanced treatments
• Regulatory complexities and the need for rigorous clinical evidence to approve new valve technologies can also slow market entry in emerging economies
• Addressing these challenges requires public-private partnerships, innovative pricing models, and expanded training programs to support the safe and effective deployment of heart valve technologies worldwide. Efforts to create cost-effective valve options and local manufacturing capabilities will be key to improving accessibility and driving equitable global growth

Heart Valve Repair and Replacement Market Scope

The market is segmented on the basis of product, procedure, indication, end user, and distribution channel.

• By Product

On the basis of product, the heart valve repair and replacement market is segmented into surgical heart valves replacement, surgical heart valves repair, TAVI/TAVR valves, grafts, patches, medication, and others. The TAVI/TAVR valves segment dominated the market with the largest market revenue share of 44.1% in 2024, driven by its minimally invasive nature, shorter recovery time, and increasing use among elderly and high-risk patients. The segment is rapidly expanding as clinical guidelines evolve and transcatheter solutions gain acceptance for intermediate and even low-risk patients.

The surgical heart valves repair segment is anticipated to witness the fastest growth from 2025 to 2032, supported by advancements in surgical techniques, rising demand for valve preservation approaches, and increasing availability of devices specifically designed for complex mitral and tricuspid repair procedures.

• By Procedure

On the basis of procedure, the heart valve repair and replacement market is segmented into surgical procedure and non-surgical procedure. The surgical procedure segment held the largest revenue share of 58.9% in 2024, owing to the historical dominance of open-heart valve surgeries, especially in mitral and tricuspid interventions. Many hospitals still rely on conventional surgical methods due to their established clinical outcomes and broader accessibility in resource-limited regions.

The non-surgical procedure segment, primarily consisting of TAVR and other catheter-based techniques, is expected to register the highest CAGR during the forecast period, driven by growing physician preference for minimally invasive techniques and expanding indications across various patient risk profiles.

• By Indication

On the basis of indication, the heart valve repair and replacement market is segmented into valvular stenosis, valvular insufficiency, mitral valve prolapse, and others. The valvular stenosis segment dominated the market with a revenue share of 46.4% in 2024, primarily due to the high prevalence of aortic stenosis among the aging population. The increased adoption of TAVR for aortic stenosis treatment has further bolstered this segment’s growth.

The mitral valve prolapse segment is expected to grow significantly during the forecast period due to rising detection rates and the increasing application of transcatheter mitral repair technologies in high-risk surgical patients.

• By End User

On the basis of end user, the heart valve repair and replacement market is segmented into hospitals, specialty centers, cardiac catheterization labs, ambulatory surgical centers, and others. The hospitals segment dominated the market with the largest share of 64.2% in 2024, attributed to the availability of advanced surgical facilities, trained cardiovascular surgeons, and post-operative care units. Hospitals also benefit from reimbursement structures that support both surgical and catheter-based procedures.

The cardiac catheterization labs segment is projected to witness the highest growth rate during forecast period , fueled by the increasing volume of transcatheter interventions and investments in expanding interventional cardiology infrastructure.

• By Distribution Channel

On the basis of distribution channel, the heart valve repair and replacement market is segmented into direct tender, retail sales, and others. The direct tender segment held the largest revenue share of 51.7% in 2024, owing to bulk procurement by hospitals and healthcare institutions, especially in government-funded and large private facilities. Direct tenders also streamline the supply chain and reduce acquisition costs for high-value devices.

The retail sales segment is expected to grow steadily during forecast period, due to the rising availability of post-surgical medications and accessories through retail pharmacies and online platforms.

Heart Valve Repair and Replacement Market Regional Analysis

• North America dominated the heart valve repair and replacement market with the largest revenue share of 39.2% in 2024, characterized by advanced healthcare infrastructure, high procedure volumes, favorable reimbursement policies, and the presence of key industry players
• Patients and providers in the region value the clinical benefits, reduced recovery times, and expanded access to innovative procedures such as TAVR and MitraClip, supported by favorable reimbursement policies and strong clinical guidelines
• This widespread procedural uptake is further reinforced by an aging population, increased cardiovascular screening, and the presence of major market players, establishing North America as a global leader in both surgical and catheter-based heart valve interventions

U.S. Heart Valve Repair and Replacement Market Insight

The U.S. heart valve repair and replacement market captured the largest revenue share of 78.3% in 2024 within North America, fueled by the widespread adoption of advanced cardiovascular procedures and favorable reimbursement policies. A high prevalence of aortic stenosis and mitral regurgitation, combined with rapid technological innovation in transcatheter valve solutions such as TAVR and MitraClip, drives market growth. The nation’s strong clinical infrastructure, robust pipeline of FDA-approved devices, and leadership in clinical trials and research further reinforce its position as a global hub for heart valve innovation.

Europe Heart Valve Repair and Replacement Market Insight

The Europe heart valve repair and replacement market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by the aging population and increasing incidence of valvular heart diseases. Stringent health guidelines and widespread screening programs are promoting early diagnosis and timely interventions. Countries across the region are investing heavily in minimally invasive cardiac care, with rising adoption of catheter-based procedures, especially in Germany, France, and Italy. The expanding geriatric demographic and increased focus on healthcare modernization continue to support long-term market growth.

U.K. Heart Valve Repair and Replacement Market Insight

The U.K. heart valve repair and replacement market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing government support for cardiac health programs and rising adoption of less invasive valve interventions. NHS investments in transcatheter therapies and the country’s focus on reducing surgical wait times are boosting patient access to timely treatment. Moreover, a growing number of heart centers and collaborations between hospitals and medtech companies are strengthening procedural volumes and clinical capabilities.

Germany Heart Valve Repair and Replacement Market Insight

The Germany heart valve repair and replacement market is expected to expand at a considerable CAGR during the forecast period, fueled by its advanced healthcare infrastructure and strong emphasis on medical innovation. Germany leads Europe in TAVR procedures, with high procedural volumes supported by experienced interventional cardiologists and well-equipped hospitals. Continuous investment in clinical research, combined with a favorable reimbursement framework, further promotes adoption across both surgical and non-surgical approaches.

Asia-Pacific Heart Valve Repair and Replacement Market Insight

The Asia-Pacific heart valve repair and replacement market is poised to grow at the fastest CAGR of 23.5% during the forecast period of 2025 to 2032, driven by rising healthcare expenditure, improved access to cardiac care, and increasing awareness of valvular heart disease. Rapid urbanization and healthcare infrastructure development in countries such as China, India, and Japan are creating a favorable environment for heart valve interventions. Local manufacturing capabilities and strategic collaborations with global medtech companies are further enhancing affordability and accessibility of advanced therapies.

Japan Heart Valve Repair and Replacement Market Insight

The Japan heart valve repair and replacement market is gaining momentum due to the country’s aging population and technological leadership in medical device adoption. Japan has seen growing use of minimally invasive valve therapies supported by government-led healthcare initiatives and regulatory support. Integration of AI in diagnostics and precise imaging tools is driving more accurate procedural planning. As the country faces rising cardiovascular disease burden, demand for both surgical and transcatheter valve replacements is steadily increasing.

India Heart Valve Repair and Replacement Market Insight

The India heart valve repair and replacement market accounted for the largest revenue share in Asia Pacific in 2024, attributed to its vast patient population, increasing awareness of cardiovascular health, and rising middle-class demand for quality healthcare. Government initiatives such as Ayushman Bharat and growing public-private partnerships are expanding access to life-saving cardiac interventions. Affordable valve solutions, a growing base of trained cardiac specialists, and rising medical tourism make India a focal point for future heart valve market expansion

Heart Valve Repair and Replacement Market Share

The heart valve repair and replacement industry is primarily led by well-established companies, including:

• Edwards Lifesciences Corporation (U.S.)
• Medtronic (Ireland)
• Abbott (U.S.)
• Boston Scientific Corporation (U.S.)
• LivaNova PLC (U.K.)
• CryoLife, Inc. (U.S.)
• Micro Interventional Devices, Inc. (U.S.)
• JenaValve Technology, Inc. (U.S.)
• Colibri Heart Valve, LLC (U.S.)
• Braile Biomédica (Brazil)
• TTK Healthcare Limited (India)
• Neovasc Inc. (Canada)
• Biotronik SE & Co. KG (Germany)
• Lepu Medical Technology (Beijing) Co., Ltd. (China)
• Meril Life Sciences Pvt. Ltd. (India)
• Xeltis AG (Switzerland)
• Peijia Medical Limited (China)
• Hansen Medical, Inc. (U.S.)
• Transcatheter Technologies GmbH (Germany)

What are the Recent Developments in Global Heart Valve Repair and Replacement Market?

• In May 2024, Medtronic plc received expanded FDA approval for its Evolut FX TAVR system to include intermediate-risk patients with aortic stenosis. This regulatory milestone reflects the growing clinical confidence in transcatheter aortic valve replacement technologies and underscores Medtronic’s leadership in advancing less invasive solutions for structural heart disease. The approval is expected to significantly broaden patient access and further accelerate the global adoption of TAVR procedures
• In March 2024, Edwards Lifesciences Corporation launched the next-generation SAPIEN X4 transcatheter heart valve system in Europe following CE Mark approval. The device introduces enhanced frame design, improved durability, and precise delivery features aimed at optimizing outcomes in aortic valve replacement. This development represents Edwards’ continued investment in innovation to meet evolving clinical needs and reinforces its leading position in the global TAVR segment
• In February 2024, Abbott Laboratories announced promising clinical trial results for its TriClip device, a transcatheter solution for tricuspid valve repair. The TRILUMINATE trial demonstrated significant improvement in heart failure symptoms and quality of life among patients with tricuspid regurgitation. These findings are expected to pave the way for regulatory approvals and drive commercial adoption, marking a significant expansion of transcatheter therapies beyond the aortic and mitral positions
• In January 2024, Boston Scientific Corporation completed the acquisition of Millipede, Inc., a company specializing in transcatheter mitral valve repair technology. The acquisition enables Boston Scientific to strengthen its structural heart portfolio and positions the company to compete in the growing market for minimally invasive mitral interventions. This strategic move aligns with the industry trend toward comprehensive transcatheter solutions
• In December 2023, JenaValve Technology, Inc. announced the successful enrollment of its ALIGN-AR pivotal trial for the JenaValve Pericardial TAVR System, targeting patients with symptomatic aortic regurgitation. As one of the few TAVR systems designed specifically for pure AR cases, this innovation addresses a critical unmet need and has the potential to open a new segment within the transcatheter valve market. JenaValve’s continued progress highlights the market’s shift toward condition-specific device development

SKU-63634